Waddah Arafat, M.D.

Waddah Arafat, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology. He serves as the Medical Director of the Clinical Cancer Informatics Program at Harold C. Simmons Comprehensive Cancer Center.

Originally from Damascus, Syria, Dr. Arafat earned his medical degree at Damascus University Faculty of Medicine. He completed internal medicine residency training at Indiana University School of Medicine in Indianapolis. He then completed advanced training through a fellowship in hematology and medical oncology at the University of Wisconsin in Madison.

Certified by the American Board of Internal Medicine in hematology and medical oncology, Dr. Arafat joined the UT Southwestern faculty in 2018.

At UT Southwestern, Dr. Arafat is the Chair of the Germ Cell Tumor Board and Deputy Chief Medical Informatics Officer. He is also a member of the Simmons Comprehensive Cancer Center Quality Assurance & Performance Improvement Committee, the Clinical Oversight Committee, and the Oncology Care Model Steering Committee.

Dr. Arafat is a member of the American Society of Clinical Oncology.

Dr. Arafat's research interests include clinical oncology, radiation oncology, germ cell tumors, urothelial cancer, and renal cell carcinoma. His findings have resulted in numerous peer-reviewed publications.

Medical School

Damascus University School of Medicine, Syria (2009)

Residency

Alshami Hospital, Syria (2010), Internal Medicine

Residency

Indiana University School of Medicine (2013), Internal Medicine

Fellowship

University of Wisconsin Health Sciences Center (2018), Hematology Oncology

• Bladder Cancer
• Kidney Cancer
• Novel Therapeutics and Biomarker Studies
• Prostate Cancer
• Testicular Cancer

Featured Publications

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma.

Schoenhals JE, Mohamad O, Christie A, Zhang Y, Li D, Singla N, Bowman I, Arafat W, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R, Adv Radiat Oncol 2021 Sep-Oct 6 5 100692

Oncologist Perspectives on Telemedicine for Patients With Cancer: A National Comprehensive Cancer Network Survey.

Tevaarwerk AJ, Chandereng T, Osterman T, Arafat W, Smerage J, Polubriaginof FCG, Heinrichs T, Sugalski J, Martin DB, JCO Oncol Pract 2021 Jul OP2100195

Disparities in Pre-Orchiectomy Sperm Cryopreservation Among Testicular Cancer Patients at a Public Safety Net Hospital and a Private Tertiary Care Center.

Patel A, Howard JM, Chertack N, Badia RR, Margulis V, Woldu SL, Courtney K, Bowman IA, Arafat W, Meng X, Bakare T, Bagrodia A, Urology 2021 Jul

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.

Bade RM, Schehr JL, Emamekhoo H, Gibbs BK, Rodems TS, Mannino MC, Desotelle JA, Heninger E, Stahlfeld CN, Sperger JM, Singh A, Wolfe SK, Niles DJ, Arafat W, Steinharter JA, Jason Abel E, Beebe DJ, Wei XX, McKay RR, Choueri TK, Lang JM, Mol Oncol 2021 Feb

Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer.

Meng X, Ahmed M, Courtney KD, Arafat W, Ibrahim I, Margulis V, Nichols C, Bagrodia A, Front Oncol 2021 11 724682

Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.

Hannan, R, Christensen, M, Robles,L, Christie, A, Garant,A, Desai, NB, Hammers, HJ, Arafat, W, Bowman, IA, Cole, S, Courtney, KD, Woldu, SL, Bagrodia, A, Margulis, V, Cadeddu, JA, Choy, H, Sher, D, Brugarolas J, Journal of Clinical Oncology 2021 39(6_suppl) p. 311-311.

Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital.

Chertack N, Ghandour RA, Singla N, Freifeld Y, Hutchinson RC, Courtney K, Bowman IA, Arafat W, Meng X, Moore JA, Aydin AM, Sagalowsky AI, Margulis V, Lotan Y, Woldu SL, Bagrodia A, Cancer 2020 10 126 19 4362-4370

Prospective Safety and Feasibility trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)

S.All, A.Diaz de Leon, O.Mohamad, H.Choy, H.Hammers, A.Sanjeevaiah, W.Arafat, K.Courtney, R.D.Timmermanm J.Brugarolas, R.Hannan International Journal of Radiation Oncology, Biology, Physics 2020 108 3, suppl_1 e896-e897

Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.

Arafat, W, Stahlfeld, C, Sperger, JM, Heninger, E, Gopalakrishnan, D, Barata, PC, Lamenza, M, Devonshire, S, Hoxha, N, Profusek, P, Rini, Bi, Ornstein, MC, Garcia, JA, Kyriakopoulos, C, Lang, JM, Grivas, P Journal of Clinical Oncology 2017 35, no. 15_suppl

Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial.

Arafat, W, Desotelle, J, Rodems, T, McKay, RR, Abel, J, Choueiri, TK, Lang, JM Journal of Clinical Oncology 2017 35, no. 15_suppl p. 4579-4579.

 Featured Books

Epidemiology of Mediastinal Germ Cell Neoplasms. In Modern Thoracic Oncology

Albany, C., W. Arafat, and L.H. Einhorn (2018). World Scientific Publishing Company, Incorporated

Clinical Presentation and Diagnosis of Mediastinal Germ Cell Neoplasms. In Modern Thoracic Oncology

Albany, C., W. Arafat, and L.H. Einhorn (2018). World Scientific Publishing Company, Incorporated.

• Fellow Award
  Wisconsin Association of Hematology and Oncology (2017)

• American Society of Clinical Oncology (2015)